Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Benzothiazinone compound, preparation method thereof and application of benzothiazinone compound as antituberculosis drug

A technology of benzothiazinone and compound is applied in the field of benzothiazinone compound and its preparation and application as an anti-tuberculosis drug, which can solve problems such as poor drugability, and achieve low cLogP value, good drugability, and excellent inhibition. effect of effect

Inactive Publication Date: 2020-06-12
SUZHOU UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004]Anti-tuberculosis drugs targeting DprE1 with benzothiazinone (BTZ) as the backbone, currently under development are BTZ043 (phase I) and pBTZ169 (phase II ), the MICs of the two compounds against the standard strain of Mycobacterium tuberculosis were 0.02 μM and 0.004 μM, respectively. Azinonone anti-tuberculosis drugs have high cLogP value and poor druggability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzothiazinone compound, preparation method thereof and application of benzothiazinone compound as antituberculosis drug
  • Benzothiazinone compound, preparation method thereof and application of benzothiazinone compound as antituberculosis drug
  • Benzothiazinone compound, preparation method thereof and application of benzothiazinone compound as antituberculosis drug

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0029] The preparation method of benzothiazinone compound of the present invention is as follows:

[0030] (1) Compound A5 is reacted with an amine compound to obtain a benzothiazinone compound;

[0031] (2) Reducing the benzothiazinone compound prepared in step (1) to obtain compound A7, which undergoes a substitution reaction to obtain the benzothiazinone compound;

[0032] Alternatively, the benzothiazinone compound prepared in step (1) is reduced to obtain compound A7, and the compound A7 undergoes a substitution reaction followed by an azide reaction to obtain a benzothiazinone compound;

[0033] Alternatively, the benzothiazinone compound prepared in step (1) undergoes an azide reaction to obtain the benzothiazinone compound.

[0034] Further, compound A3 is chlorinated to obtain compound A4; compound A4 is reacted with isothiocyanate to obtain compound A5; A4 to A6 are one-pot reactions.

[0035] Specifically, the preparation of each compound of the present invention ...

Embodiment 1

[0044] Example 1 Compound 1: 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(methylsulfonyl)-8-nitro-4 H -Benzo[ e ][1,3]thiazin-4-one

[0045]

[0046] Dissolve ammonium thiocyanate (46 mg, 1.2 eq.) in 5 mL of anhydrous acetone, add polyethylene glycol (0.05 eq, based on compound A3) dropwise, and stir until dissolved at room temperature to obtain isothiocyanate ammonium solution;

[0047] Compound A3 (50 mg, 1eq, R 3 is methyl) dissolved in dichloromethane (anhydrous) (5 mL), dropwise N, N - Dimethylformamide (0.05eq., based on compound A3), add dropwise oxalyl chloride (0.25 mL, 2.5eq.), stir at room temperature for 0.5 hours after the addition is complete, spin dry the solvent and excess oxalyl chloride to obtain the corresponding intermediate acid chloride compound (compound A4, R 3 is methyl); then dropwise add the above-mentioned ammonium isothiocyanate solution, and stir at room temperature for 20 minutes after the dropwise addition is completed, to obtain intermedi...

Embodiment 2

[0049] Example 2 Compound 2: 2-(benzyl(methyl)amino)-6-(methylsulfonyl)-8-nitro-4 H -Benzo[ e ][1,3]thiazin-4-one

[0050]

[0051] Same operation as in Example 1, the amine used is N -Methyl-1-phenylmethanamine, and the rest remain unchanged to obtain compound 2 as a yellow solid (yield 52%).

[0052] 1H NMR (400 MHz, CDCl3) δ 9.34 (s, 1H), 9.04 (s, 1H), 7.33 – 7.26 (m,5H), 5.13 – 4.94 (m, 2H), 3.40 – 3.29 (m, 3H), ( / z): 405.7 [M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a benzothiazinone compound, a preparation method thereof and an application of the benzothiazinone compound as an antituberculosis drug, and particularly relates to a novel compound with a benzothiazinone skeleton. The compound has an inhibition effect on tubercle bacillus, especially tubercle bacillus with clinical drug resistance. Results show that the compound shows an obvious antibacterial effect, the antibacterial effect far exceeds that of a positive control isoniazide, and particularly, compared with a positive control pBTZ169, the compound has an obviously goodcLogP value.

Description

technical field [0001] The technical field of the present invention relates to the application of antibacterial drugs, mainly for the research and development of drugs for bacilli, such as Mycobacterium tuberculosis or Bacillus leprae, after infecting the human body; specifically, it relates to a new class of compounds with a benzothiazinone skeleton. It has been shown to have an inhibitory effect on Mycobacterium tuberculosis, especially it also has an inhibitory effect on Mycobacterium tuberculosis with clinical drug resistance. Background technique [0002] As a developing country, China currently has about 4.5 million tuberculosis patients, the second largest number of tuberculosis patients in the world, and about 450,000 people die of tuberculosis every year. Tuberculosis has become a serious public health problem. The main problem with existing clinical medications is that they cannot effectively control multidrug-resistant and broad-spectrum drug-resistant bacteria. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D279/08C07D417/12A61P31/06A61K31/5415
CPCC07D279/08C07D417/12A61P31/06Y02A50/30
Inventor 乔春华
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products